What are Prime Medicine's total assets?

Prime Medicine (PRME) holds $294.7M in total assets, down 10.2% year over year.

How much debt does Prime Medicine have?

Prime Medicine carries $114.5M in total debt against $76.7M of shareholders' equity, a debt-to-equity ratio of 1.49.

How much cash does Prime Medicine have?

Prime Medicine holds $77.8M in cash and equivalents.

Can Prime Medicine cover its short-term obligations?

Its current ratio is 3.80 — current assets exceed current liabilities.

Where does Prime Medicine's balance sheet data come from?

Every line is extracted from Prime Medicine's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Prime Medicine PRME Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$77.8M-26.6%	$76.72M-61.0%	$85.09M-35.6%	$67.5M-2.3%	$105.94M-1.6%
Short-term investments	——	——	——	——	——
Restricted cash	$13.69M-2.6%	$13.69M-2.6%	$13.69M-2.6%	$13.69M+1.4%	$14.06M+4.2%
Accounts receivable, net	——	——	-$120K-100%	$120K—	$17K—
Prepaid expenses and other current assets	$10.44M-47.6%	$11.41M-46.1%	$15.25M-54.4%	$18.76M-59.8%	$19.93M-62.6%
Trading assets	$71.39M+47.3%	$114.65M+3,724%	$137.03M+160%	$44.54M-56.6%	$48.47M-55.9%
Total current assets	$137.89M-15.8%	$181.29M-14.4%	$231.41M-6.0%	$121.29M-29.0%	$163.77M-24.8%
Property and equipment, net	$18.82M-24.6%	$20.57M-15.7%	$22.05M-5.3%	$23.83M+0.1%	$24.96M+4.3%
Accumulated depreciation	$22.29M+45.7%	$20.43M+50.3%	$18.56M+56.2%	$16.68M+61.3%	$15.3M+73.8%
Operating lease right-of-use assets	$123.33M-1.6%	$126.18M+168%	$117.87M+139%	$120.2M+133%	$125.38M+126%
Other non-current assets	——	——	——	——	——
Total assets	$294.73M-10.2%	$342.73M+15.2%	$385.01M+15.7%	$279.01M+7.4%	$328.16M+5.4%
Accounts payable	$36.94M+17.5%	$34.64M+10.0%	$37.11M-6.5%	$33.18M-31.4%	$31.44M-36.1%
Accrued expenses	$2.19M-47.6%	$7.34M-53.9%	$6.76M-10.0%	$5.82M+16.7%	$4.18M—
Deferred revenue	$7.32M—	$7.82M—	$6.95M—	$8.32M—	——
Operating lease liabilities, current	$8.55M+24.6%	$8.14M+125%	$7.71M+72.0%	$7.26M+39.1%	$6.86M+1.6%
Contract liabilities	$57.78M—	$58.13M—	$59.75M—	$59.56M—	——
Total current liabilities	$36.29M+5.8%	$37.45M-1.4%	$35.02M-7.5%	$34.11M+64.4%	$34.29M+40.3%
Operating lease liabilities, non-current	$105.97M-7.3%	$108.29M+191%	$110.42M+200%	$112.48M+209%	$114.29M+209%
Operating Lease Liabilities (Total)	$114.51M-5.5%	$116.43M+185%	$118.14M+186%	$119.74M+188%	$121.15M+177%
Total liabilities	$218.03M-1.5%	$221.87M+53.7%	$223.19M+55.8%	$218.15M+246%	$221.24M+227%
Common stock	775M0.0%	775M+38,749,900%	775M0.0%	775M0.0%	775M0.0%
Additional paid-in capital	$1.01B+19.9%	$1.01B+20.1%	$1B+20.3%	$852.56M+8.0%	$846.04M+8.3%
Retained earnings	-$937.48M-26.8%	-$888.35M-29.3%	-$842.28M-30.6%	-$791.69M-33.6%	-$739.1M-37.6%
Accumulated other comprehensive income (loss)	-$1K+93.3%	$82K+8,100%	$33K+57.1%	-$10K+85.9%	-$15K+84.2%
Total stockholders' equity	$76.7M-28.3%	$120.87M-21.1%	$161.82M-14.6%	$60.86M-69.0%	$106.92M-56.1%
Total liabilities and stockholders' equity	$294.73M-10.2%	$342.73M+15.2%	$385.01M+15.7%	$279.01M+7.4%	$328.16M+5.4%
Available-for-Sale Debt Securities - Amortized Cost	$71.39M+47.3%	$114.57M+3,723%	$137M+160%	$44.55M-56.6%	$48.48M-55.9%
Cash, Cash Equivalents, and Marketable Securities	$71.39M+47.3%	$114.65M+3,724%	$137.03M+160%	$44.54M-56.6%	$48.47M-55.9%
Available For Sale Securities Debt Securities Current	——	——	——	——	——
Cash Cash Equivalents And Short Term Investments	——	——	——	——	——
Other current assets	$421K-97.5%	$674K-95.4%	$15.63M+63.8%	$16.39M—	$16.54M—
Deferred Tax Assets and Other Non-Current Assets	——	——	——	——	——
Investments - Amortized Cost Basis	$71.39M+47.3%	$114.57M+3,723%	$137M+160%	$44.55M-56.6%	$48.48M-55.9%
Net Investment in Lease	$123.33M-1.6%	$126.18M+168%	$117.87M+139%	$120.2M+133%	$125.38M+126%
Operating lease right-of-use assets	$123.33M-1.6%	$126.18M+168%	$117.87M+139%	$120.2M+133%	$125.38M+126%
Other non-current assets	——	——	——	——	——
Property, plant and equipment at cost	$41.11M+2.1%	$41.01M+7.9%	$40.6M+15.5%	$40.5M+18.6%	$40.25M+23.0%
Operating Lease Right-of-Use Assets in Other Assets	$123.33M-1.6%	$126.18M+168%	$117.87M+139%	$120.2M+133%	$125.38M+126%
Software and Technology Licenses, Net	——	——	——	——	——
Accrued Manufacturing Costs	$2.19M-47.6%	$7.34M—	$6.76M—	$5.82M—	$4.18M—
Accrued Progress Collections and Price Adjustments	$57.78M—	$58.13M—	$59.75M—	$59.56M—	——
Other Commercial Liabilities	$8.1M-11.9%	$12.6M-20.8%	$11M-41.1%	$12.16M+11.6%	$9.19M—
Accrued Liabilities, Current	$8.1M-11.9%	$12.6M-20.8%	$11M-41.1%	$12.16M+11.6%	$9.19M—
Compensation and benefits	$2.19M-47.6%	$7.34M—	$6.76M—	$5.82M—	$4.18M—
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——	——
Contract Liabilities, Non-Current	$57.78M—	$58.13M—	$59.75M—	$59.56M—	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——	——
Deferred revenue, net of current portion	$57.78M—	$58.13M—	$59.75M—	$59.56M—	——
Total debt	$114.51M-5.5%	$116.43M+185%	$118.14M+186%	$119.74M+188%	$121.15M+177%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	180.6M+37.7%	180.5M+37.6%	180.3M+37.5%	134.5M+12.0%	131.2M+9.3%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$2K0.0%	$2K0.0%	$2K0.0%	$2K0.0%	$2K0.0%
Number of Exercisable Options	——	——	——	——	——
Number of Vested and Expected to Vest Options	——	——	——	——	——
Share-Based Payment Award Options Outstanding - Number	20.9M+36.2%	15.6M+37.0%	15.6M+33.4%	16.8M+44.9%	15.3M+34.6%
Unrealized Gains on Investments	$12K—	$85K+8,400%	$40K+81.8%	$0—	$0—
Unrealized Losses on Investments (Before Tax)	$13K-13.3%	$3K—	$7K—	$10K-85.7%	$15K-81.9%
Weighted Average Exercise Price of Outstanding Options	$3.71-48.5%	$3.76-36.4%	$3.70-59.3%	$6.14-33.0%	$7.21-22.0%
Weighted Average Exercise Price of Vested and Expected to Vest Options	——	——	——	——	——
Cumulative Cost Basis	$71.39M+47.3%	$114.57M+3,723%	$137M+160%	$44.55M-56.6%	$48.48M-55.9%
License fee	$1.56M—	$1.56M—	$1.56M—	$1.56M—	——
Research and clinical costs	$2.2M—	$2M—	$619K—	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$13K-13.3%	$3K—	$7K—	$10K-85.7%	$15K-81.9%
Gross Unrealized Gains	$12K—	$85K+8,400%	$40K+81.8%	$0—	$0—
Total	$71.39M+47.3%	$114.57M+3,723%	$137M+160%	$44.55M-56.6%	$48.48M-55.9%
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	$71.39M+47.3%	$114.65M+3,724%	$137.03M+160%	$44.54M-56.6%	$48.47M-55.9%
Available for sale investments	$71.39M+47.3%	$114.65M+3,724%	$137.03M+160%	$44.54M-56.6%	$48.47M-55.9%
Number of votes per common share	——	——	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, par value under amendment (in dollars per share)	——	——	——	——	——
Common stock, shares authorized (in shares)	$775M0.0%	$775M0.0%	$775M0.0%	$775M0.0%	$775M0.0%
Common stock, shares issued (in shares)	$180.62M+37.7%	$180.51M+37.6%	$180.31M+37.5%	$134.49M+12.0%	$131.16M+9.3%
Common Stock, Shares, Outstanding	$180.62M+37.7%	$180.51M+37.6%	$180.31M+37.5%	$134.49M+12.0%	$131.16M+9.3%
Lessee Operating Lease Liability Payments Due	——	——	——	——	——
Thereafter	——	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——	——
Other accrued liabilities	$2.15M-20.9%	$1.7M—	$2.06M—	$1.12M—	$2.72M—
Prepaid expenses	$1.97M-33.1%	$2.94M-56.6%	$2.49M-58.5%	$3.03M—	$2.95M—
Research and development funding liability	$18M+50.0%	$18M+200%	$18M+200%	$12M—	$12M—
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$20.88M+36.2%	$15.64M+37.0%	$15.58M+33.4%	$16.84M+44.9%	$15.33M+34.6%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$3.71-48.5%	$3.76-36.4%	$3.7-59.3%	$6.14-33.0%	$7.21-22.0%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Prime Medicine.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Prime Medicine's total assets?: Prime Medicine (PRME) holds $294.7M in total assets, down 10.2% year over year.
How much debt does Prime Medicine have?: Prime Medicine carries $114.5M in total debt against $76.7M of shareholders' equity, a debt-to-equity ratio of 1.49.
How much cash does Prime Medicine have?: Prime Medicine holds $77.8M in cash and equivalents.
Can Prime Medicine cover its short-term obligations?: Its current ratio is 3.80 — current assets exceed current liabilities.
Where does Prime Medicine's balance sheet data come from?: Every line is extracted from Prime Medicine's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.